MX2021003232A - Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa. - Google Patents

Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.

Info

Publication number
MX2021003232A
MX2021003232A MX2021003232A MX2021003232A MX2021003232A MX 2021003232 A MX2021003232 A MX 2021003232A MX 2021003232 A MX2021003232 A MX 2021003232A MX 2021003232 A MX2021003232 A MX 2021003232A MX 2021003232 A MX2021003232 A MX 2021003232A
Authority
MX
Mexico
Prior art keywords
sup
glucopyranosidase
acetamido
deoxy
glycoprotein
Prior art date
Application number
MX2021003232A
Other languages
English (en)
Inventor
Lei Zhang
Zhili Xin
Nathan Genung
Kevin M Guckian
Jeffrey Vessels
Ryan Gianatassio
Edward Yin Shiang Lin
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MX2021003232A publication Critical patent/MX2021003232A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

En la presente se describen compuestos representados por las fórmulas (IA) o (IB) (ver Fórmulas) (IA) (IB) o una sal farmacéuticamente aceptable de estos, composiciones farmacéuticas que los comprenden y métodos para prepararlos y utilizarlos; las variables R1, R3, R4, Y1, Y2, Ar, Z y n son como se definen en la presente.
MX2021003232A 2018-09-19 2019-09-18 Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa. MX2021003232A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862733484P 2018-09-19 2018-09-19
US201862750000P 2018-10-24 2018-10-24
PCT/US2019/051661 WO2020061150A1 (en) 2018-09-19 2019-09-18 O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Publications (1)

Publication Number Publication Date
MX2021003232A true MX2021003232A (es) 2021-07-16

Family

ID=68073263

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003232A MX2021003232A (es) 2018-09-19 2019-09-18 Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.

Country Status (21)

Country Link
US (1) US20220041586A1 (es)
EP (1) EP3853226A1 (es)
JP (1) JP2022500472A (es)
KR (1) KR20210060513A (es)
CN (1) CN113166137A (es)
AU (1) AU2019344922A1 (es)
BR (1) BR112021004739A2 (es)
CA (1) CA3113009A1 (es)
CL (1) CL2021000646A1 (es)
CO (1) CO2021004873A2 (es)
CR (1) CR20210181A (es)
IL (1) IL281514A (es)
JO (1) JOP20210036A1 (es)
MA (1) MA53648A (es)
MX (1) MX2021003232A (es)
PE (1) PE20211591A1 (es)
PH (1) PH12021550439A1 (es)
SG (1) SG11202102379XA (es)
TW (1) TW202031651A (es)
UY (1) UY38376A (es)
WO (1) WO2020061150A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230286972A1 (en) * 2020-08-03 2023-09-14 Biogen Ma Inc. Crystaline forms of an o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitor
KR102533471B1 (ko) * 2020-11-23 2023-05-19 (주) 메디프론디비티 O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO2013075083A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
NZ628762A (en) 2012-02-10 2016-07-29 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
KR102219441B1 (ko) 2013-02-11 2021-02-23 콘스텔레이션 파마슈티칼스, 인크. 메틸 변형 효소 조절제, 이의 조성물 및 용도
AU2014241065B2 (en) * 2013-03-14 2017-08-31 Merck Patent Gmbh Glycosidase inhibitors
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
CA3044762A1 (en) * 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Bicyclic oga inhibitor compounds
US20200079766A1 (en) * 2016-12-16 2020-03-12 Janssen Pharmaceutica Nv Monocyclic oga inhibitor compounds
AR110747A1 (es) 2017-01-27 2019-05-02 Lilly Co Eli Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo
EP3765458B1 (en) * 2018-03-14 2023-01-11 Biogen MA Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors

Also Published As

Publication number Publication date
CO2021004873A2 (es) 2021-07-30
MA53648A (fr) 2021-07-28
CL2021000646A1 (es) 2021-09-03
EP3853226A1 (en) 2021-07-28
UY38376A (es) 2020-04-30
BR112021004739A2 (pt) 2021-06-01
AU2019344922A1 (en) 2021-03-25
CN113166137A (zh) 2021-07-23
TW202031651A (zh) 2020-09-01
US20220041586A1 (en) 2022-02-10
CR20210181A (es) 2021-07-01
WO2020061150A1 (en) 2020-03-26
SG11202102379XA (en) 2021-04-29
JOP20210036A1 (ar) 2021-02-25
JP2022500472A (ja) 2022-01-04
IL281514A (en) 2021-04-29
CA3113009A1 (en) 2020-03-26
PH12021550439A1 (en) 2021-11-29
KR20210060513A (ko) 2021-05-26
PE20211591A1 (es) 2021-08-18

Similar Documents

Publication Publication Date Title
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
CA3057882A1 (en) Substituted dihydro-spiro-napthalene-oxa derivatives and pharmaceutical compositions thereof useful as inhibitors of mcl-1 protein
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
WO2017019804A3 (en) Compounds and methods for kinase modulation, and indications therefor
TN2017000521A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
WO2019165043A3 (en) Indane-amines as pd-l1 antagonists
EP4316591A3 (en) Oxysterols and methods of use thereof
WO2020257549A3 (en) Compounds for treatment of pd-l1 diseases
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MX2021012105A (es) Compuestos de pirrol.
MX2021007247A (es) Derivados de rapamicina.
MX2021014680A (es) Derivado de benzotriazol.
WO2018039077A8 (en) Therapeutic compounds
MX2022003504A (es) Inhibidor de irak y metodo de preparacion para el mismo y uso del mismo.
PH12019550154A1 (en) Azetidine derivative
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
ZA202204442B (en) Salt forms of a complement component c5a receptor
PH12021550439A1 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
MX2022006104A (es) Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma.
MX2021004379A (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
WO2020139971A3 (en) Methods for making dimeric naphthalimides and solid state forms of the same